Literature DB >> 30737996

PRISModegib: the use of the PRISM test to assess the health-related quality of life of patients with locally advanced basal cell carcinoma undergoing Hedgehog pathway inhibitor therapy.

G Gualdi1, R Moro1, V Regina1, S Caravello1, P Monari1, P G Calzavara-Pinton1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30737996     DOI： 10.1111/bjd.17754

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN： 0007-0963            Impact factor:   9.302


× No keyword cloud information.
  1 in total

1.  Long-Term Efficacy of Vismodegib After its Withdrawal and Patients' Health-Related Quality of Life Using the Dermatology Life Quality Index (DLQI).

Authors:  Alessia Villani; Matteo Megna; Gabriella Fabbrocini; Milena Cappello; Maria Antonietta Luciano; Claudia Costa; Massimiliano Scalvenzi
Journal:  Dermatol Ther (Heidelb)       Date:  2019-09-10
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.